News Snapshot:
The Janssen unit of Johnson & Johnson (NYSE:JNJ) announced Tuesday that its parent company will incur a ~10c annual negative impact on 2023 and 2024 earnings per share as a result of a deal with Cellular Biomedicine Group (CBMG) for CAR T-cell therapies. However, the company maintained its 2023 guidance and noted that the negative impact would primarily hurt its financials for Q2 2023, when the transaction is expected to close. The CD20-directed autologous CAR-Ts that Janssen licenses from CBMG have indicated favorable overall and complete response rates in Phase 1 studies for patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) in...
